The Lancet Oncology最新文献

筛选
英文 中文
Oligometastatic prostate cancer: time to integrate metastasis-directed therapy 少转移性前列腺癌:整合转移导向治疗的时间
The Lancet Oncology Pub Date : 2026-02-02 DOI: 10.1016/s1470-2045(25)00760-0
Simon K B Spohn, Anca-Ligia Grosu
{"title":"Oligometastatic prostate cancer: time to integrate metastasis-directed therapy","authors":"Simon K B Spohn, Anca-Ligia Grosu","doi":"10.1016/s1470-2045(25)00760-0","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00760-0","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146109903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ezabenlimab with induction chemotherapy and adaptive chemoradiotherapy in stage 3 squamous cell anal carcinoma ezabenliumab联合诱导化疗和适应性放化疗治疗3期鳞状细胞癌
The Lancet Oncology Pub Date : 2026-02-02 DOI: 10.1016/s1470-2045(26)00001-x
Bhumesh Tyagi, Leelabati Toppo, Aishwarya Biradar
{"title":"Ezabenlimab with induction chemotherapy and adaptive chemoradiotherapy in stage 3 squamous cell anal carcinoma","authors":"Bhumesh Tyagi, Leelabati Toppo, Aishwarya Biradar","doi":"10.1016/s1470-2045(26)00001-x","DOIUrl":"https://doi.org/10.1016/s1470-2045(26)00001-x","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"58 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146109901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiotherapy has a role to play in patients with EGFR-mutated non-small-cell lung cancer in first-line treatment 放疗在egfr突变的非小细胞肺癌患者的一线治疗中发挥着重要作用
The Lancet Oncology Pub Date : 2026-02-02 DOI: 10.1016/s1470-2045(25)00756-9
Dirk De Ruysscher, Pim J J Damen, Lizza E L Hendriks, Stephanie P L Saw
{"title":"Radiotherapy has a role to play in patients with EGFR-mutated non-small-cell lung cancer in first-line treatment","authors":"Dirk De Ruysscher, Pim J J Damen, Lizza E L Hendriks, Stephanie P L Saw","doi":"10.1016/s1470-2045(25)00756-9","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00756-9","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"294 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146109913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to Lancet Oncol 2026; 27: 11–12 Lancet Oncol 2026修正;27日:11 - 12
The Lancet Oncology Pub Date : 2026-02-02 DOI: 10.1016/s1470-2045(25)00757-0
{"title":"Correction to Lancet Oncol 2026; 27: 11–12","authors":"","doi":"10.1016/s1470-2045(25)00757-0","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00757-0","url":null,"abstract":"<em>Cattley RC, De Roos AJ, Mandrioli D, et al. Carcinogenicity of atrazine, alachlor, and vinclozolin.</em> Lancet Oncol <em>2026; <strong>27:</strong> 11–12</em>—In this News, the meta-odds ratio in the second sentence of the fifth paragraph should have been 1·99; 95% CI 1·13–3·53. This correction has been made to the online version as of Feb 2, 2026.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"89 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146101567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Estimated effect of correcting inequalities in minimally invasive surgical resection in patients with colon cancer in England: a population-based study 英国结肠癌患者微创手术切除中纠正不平等的估计效果:一项基于人群的研究
The Lancet Oncology Pub Date : 2026-02-02 DOI: 10.1016/s1470-2045(25)00648-5
Camille Maringe, Daniel O’Leary, Sara Benitez-Majano, Clemence Leyrat, Aimilia Exarchakou, Bernard Rachet, Manuela Quaresma
{"title":"Estimated effect of correcting inequalities in minimally invasive surgical resection in patients with colon cancer in England: a population-based study","authors":"Camille Maringe, Daniel O’Leary, Sara Benitez-Majano, Clemence Leyrat, Aimilia Exarchakou, Bernard Rachet, Manuela Quaresma","doi":"10.1016/s1470-2045(25)00648-5","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00648-5","url":null,"abstract":"&lt;h3&gt;Background&lt;/h3&gt;Minimally invasive surgical resection offers advantages over open surgical resection in elective management of colon cancer. However, patients who are older, have comorbidities, or live in socioeconomically deprived areas are less likely to receive minimally invasive surgical resection. We aimed to estimate the potential effect on outcomes of correcting inequalities in minimally invasive surgical resection for colon cancer.&lt;h3&gt;Methods&lt;/h3&gt;In this population-based study, we studied adult patients (aged 15–99 years) diagnosed with stage I–III carcinoma of the colon between Jan 1 and Dec 31, 2022, and followed up to Dec 31, 2023, who underwent elective resection as recorded in linked cancer registration data in England. We excluded patients diagnosed through an emergency route, diagnosed with metastatic disease (stage IV), with missing stage, not resected, and who underwent colon cancer surgery in a private hospital or in a UK National Health Service (NHS) Trust that recorded ten or fewer colon cancer resections in 2022. Only Trusts doing both minimally invasive surgical and open surgical resections were included to ensure correct modelling of the effect of correcting inequalities in minimally invasive surgical resections within each Trust. We designed scenarios to correct inequalities in minimally invasive surgical resection in each UK NHS Trust, targeting four suboptimal uptake groups (patients who were aged 65 years and older, patients with frailty, patients with comorbidities, and patients with high levels of socioeconomic deprivation). We used a potential outcomes framework and contrasted observed and potential outcomes to estimate the effect of reducing inequalities in use of minimally invasive surgical resection on four primary outcomes: the lengths of index stay and total hospital stay, the probability of readmission within 30 days of resection, and 1-year mortality after resection.&lt;h3&gt;Findings&lt;/h3&gt;All analyses included data for 10 603 elective colon resections done in 123 NHS Trusts. The median follow-up time was 1·47 years (IQR 1·22–1·74). The mean age at diagnosis was 70·3 years (SD 11·4). 5487 (51·7%) patients were male and 5116 (48·3%) were female. Minimally invasive surgical resection was attempted in 8909 (84·0%) and completed in 7951 (75·0%), among whom there were substantial inequalities in the proportion of minimally invasive surgical resections among the four suboptimal uptake groups defined by age at diagnosis of 65 years and older (5495 [73·8%] &lt;em&gt;vs&lt;/em&gt; 2456 [77·8%] in those younger than 65 years), most deprived quintiles (quintiles 3–5: 4114 [73·9%] &lt;em&gt;vs&lt;/em&gt; 3837 [76·2%] in the least deprived quintiles), comorbidity (2348 [70·8%] &lt;em&gt;vs&lt;/em&gt; 5603 [76·9%] in those without comorbidities), and a moderate or high frailty score (695 [64·1%] &lt;em&gt;vs&lt;/em&gt; 7256 [76·2%] in those with a low frailty score). Patients with minimally invasive surgical resection had 3-day to 4-day shorter lengths of hospital stay than ","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"67 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146109893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
International Multidisciplinary Consensus Group for Malignant Spinal Cord Compression: recommendations for definitions, reporting items, and study endpoints for clinical trials and audits 恶性脊髓压迫国际多学科共识小组:对临床试验和审计的定义、报告项目和研究终点的建议
The Lancet Oncology Pub Date : 2026-02-02 DOI: 10.1016/s1470-2045(25)00602-3
{"title":"International Multidisciplinary Consensus Group for Malignant Spinal Cord Compression: recommendations for definitions, reporting items, and study endpoints for clinical trials and audits","authors":"","doi":"10.1016/s1470-2045(25)00602-3","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00602-3","url":null,"abstract":"Malignant spinal cord compression (MSCC) is a serious complication of spinal metastases and primary spinal tumours that can severely affect quality of…","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146101573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inverse care law and inequity of access to patient-centric care 逆护理法和以患者为中心的护理的不平等
The Lancet Oncology Pub Date : 2026-02-02 DOI: 10.1016/s1470-2045(25)00710-7
Bipin Thomas Varghese
{"title":"Inverse care law and inequity of access to patient-centric care","authors":"Bipin Thomas Varghese","doi":"10.1016/s1470-2045(25)00710-7","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00710-7","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146109891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thank you to The Lancet Oncology's reviewers in 2025 感谢《柳叶刀肿瘤学》2025年的审稿人
The Lancet Oncology Pub Date : 2026-02-02 DOI: 10.1016/s1470-2045(26)00020-3
{"title":"Thank you to The Lancet Oncology's reviewers in 2025","authors":"","doi":"10.1016/s1470-2045(26)00020-3","DOIUrl":"https://doi.org/10.1016/s1470-2045(26)00020-3","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146109905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cancer: another casualty of geopolitical unrest? 巨蟹座:地缘政治动荡的又一个牺牲品?
The Lancet Oncology Pub Date : 2026-02-02 DOI: 10.1016/s1470-2045(26)00021-5
{"title":"Cancer: another casualty of geopolitical unrest?","authors":"","doi":"10.1016/s1470-2045(26)00021-5","DOIUrl":"https://doi.org/10.1016/s1470-2045(26)00021-5","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146101566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to Lancet Oncol 2026; 27: 90–102 Lancet Oncol 2026修正;27日:90 - 102
The Lancet Oncology Pub Date : 2026-02-02 DOI: 10.1016/s1470-2045(26)00004-5
{"title":"Correction to Lancet Oncol 2026; 27: 90–102","authors":"","doi":"10.1016/s1470-2045(26)00004-5","DOIUrl":"https://doi.org/10.1016/s1470-2045(26)00004-5","url":null,"abstract":"<em>Sun J-M, Chao Y, Kim S-B, et al. First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial.</em> Lancet Oncol <em>2026; <strong>27:</strong> 90–102</em>—This Article was published with the incorrect appendix file. The file has been corrected as of Feb 2, 2026.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"30 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146101568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书